Who
Jess Roper
Director
Company insider
Files Form 4 as: Director, Revelation Biosciences; Director, Biolase; SVP, CFO, DexCom.
In numbers
- Trades disclosed
- 190
- Buys
- 1
- Sells
- 41
- Bought
- $7,614
- Sold
- $17.3M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 2 Aug 2007
- Last trade
- 17 Aug 2026
- Last filed
- 18 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Aug 2026filed 18 Aug 2026 | REVB Revelation BiosciencesBiotechnology | SEC FORM 4 Code A | —32,011 at $0.00 | filing |
| 17 Aug 2026filed 18 Aug 2026 | REVB Revelation BiosciencesBiotechnology | SEC FORM 4 Code A | —32,011 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | REVB Revelation BiosciencesBiotechnology | SEC FORM 4 Code F | $2,9431,591 at $1.85 | filing |
| 3 Feb 2026filed 5 Feb 2026 | REVB Revelation BiosciencesBiotechnology | SEC FORM 4 Code F | $2,9431,591 at $1.85 | filing |
| 8 Jan 2026filed 12 Jan 2026 | REVB Revelation BiosciencesBiotechnology | SEC FORM 4 Code A | $38K41,981 at $0.90 | filing |
| 8 Jan 2026filed 12 Jan 2026 | REVB Revelation BiosciencesBiotechnology | SEC FORM 4 Code A | $38K41,981 at $0.90 | filing |
| 29 Oct 2025filed 31 Oct 2025 | REVB Revelation BiosciencesBiotechnology | SEC FORM 4 Code A | $20K15,625 at $1.28 | filing |
| 11 Feb 2025filed 13 Feb 2025 | REVB Revelation BiosciencesBiotechnology | SEC FORM 4 Code A | $700181 at $3.87 | filing |
| 8 Jun 2023filed 12 Jun 2023 | Biolaseoption or derivative | SEC FORM 4 Code A | —512,821 at $0.00 | filing |
| 14 Apr 2023filed 18 Apr 2023 | REVB Revelation Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,356 at $0.00 | filing |
| 11 May 2022filed 13 May 2022 | Biolaseoption or derivative | SEC FORM 4 Code A | —41,775 at $0.00 | filing |
| 28 Apr 2022filed 2 May 2022 | Biolase | SEC FORM 4 Code D | —345.86 | filing |
| 11 Jun 2021filed 14 Jun 2021 | Biolaseoption or derivative | SEC FORM 4 Code A | —111,337 at $0.00 | filing |
| 11 Jun 2021filed 14 Jun 2021 | Biolaseoption or derivative | SEC FORM 4 Code A | —138,000 at $0.00 | filing |
| 6 Aug 2020filed 10 Aug 2020 | Biolaseoption or derivative | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 13 May 2020filed 28 May 2020 | Biolaseoption or derivative | SEC FORM 4 Code A | —165,245 at $0.00 | filing |
| 13 May 2020filed 28 May 2020 | Biolaseoption or derivative | SEC FORM 4 Code A | —187,378 at $0.00 | filing |
| 7 Aug 2019filed 9 Aug 2019 | Biolaseoption or derivative | SEC FORM 4 Code A | —75,152 at $0.00 | filing |
| 15 Jun 2018filed 19 Jun 2018 | Biolaseoption or derivative | SEC FORM 4 Code A | —83,333 at $0.00 | filing |
| 22 Mar 2017filed 24 Mar 2017 | DXCM DexComMedical Devices | SEC FORM 4 Sold | $152K2,000 at $75.97 | filing |
News
Vontobel Holding Ltd. Sells 14,970 Shares of DexCom, Inc. $DXCMDXCM · dailypolitical.com · 20 Oct 2026
0 headlines in the last 90 days name Jess Roper; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.